Article

Angiotensin-Converting Enzyme 2 Deficiency in Whole Body or Bone Marrow-Derived Cells Increases Atherosclerosis in Low-Density Lipoprotein Receptor(-/-) Mice

Graduate Center for Nutritional Sciences, Rm 521b, Wethington Bldg, 900 S Limestone, University of Kentucky, Lexington, KY 40536-0200, USA.
Arteriosclerosis Thrombosis and Vascular Biology (Impact Factor: 6). 03/2011; 31(4):758-65. DOI: 10.1161/ATVBAHA.110.221614
Source: PubMed

ABSTRACT

The renin-angiotensin system contributes to atherosclerotic lesion formation. Angiotensin-converting enzyme 2 (ACE2) catabolizes angiotensin II (Ang II) to angiotensin 1-7 (Ang-(1-7)) to limit effects of the renin-angiotensin system. The purpose of this study was to define the role of ACE2 in atherosclerosis.
Male Ace2(-/y) mice in an low-density lipoprotein receptor-deficient background were fed a high-fat diet for 3 months. ACE2 deficiency increased atherosclerotic area (Ace2(+/y), 17 ± 1; Ace2(-/y), 23 ± 2 mm(2), P < 0.002). This increase was blunted by losartan. To determine whether leukocytic ACE2 influenced atherosclerosis, irradiated low-density lipoprotein receptor-deficient male mice were repopulated with bone marrow-derived cells from Ace2(+/y) or Ace2(-/y) mice and fed a high-fat diet for 3 months. ACE2 deficiency in bone marrow-derived cells increased atherosclerotic area (Ace2(+/y), 1.6 ± 0.3; Ace2(-/y), 2.8 ± 0.3 mm(2); P < 0.05). Macrophages from Ace2(-/y) mice exhibited increased Ang II secretion and elevated expression of inflammatory cytokines. Conditioned media from mouse peritoneal macrophages of Ace2(-/y) mice increased monocyte adhesion to human umbilical vein endothelial cells. Incubation of human umbilical vein endothelial cells with Ang II promoted monocyte adhesion, which was blocked by Ang-(1-7). Coinfusion of Ang-(1-7) with Ang II reduced atherosclerosis.
These results demonstrate that ACE2 deficiency in bone marrow-derived cells promotes atherosclerosis through regulation of Ang II/Ang-(1-7) peptides.

Download full-text

Full-text

Available from: Xuan Zhang
  • Source
    • "Recent studies showed that local RAS modulate hematopoietic and cardiovascular reparative functions of BMSPCs (Rodgers and diZerega, 2013). We and others have shown evidence for the expression of mRNA and protein of ACE or ACE2 in human and mouse BMSPCs (Abali et al., 2002; Oliveira et al., 2010; Thatcher et al., 2011; Jarajapu et al., 2013; Singh et al., 2015). Activity assay is a reliable measure of functional ACE or ACE2, and assays were mostly based on the propensity to cleave a surrogate substrate, fluorogenic peptides MCA-RPPGFSAFK-Dnp and 7-Mca- YVADAPK(Dnp) for ACE and ACE2, respectively (Joyner et al., 2012; Liu et al., 2010; Rice et al., 2004; Wösten-van Asperen et al., 2008; Ye et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin-converting enzymes, ACE and ACE2, are key members of renin angiotensin system. Activation of ACE2/Ang-(1-7) pathway enhances cardiovascular protective functions of bone marrow-derived stem/progenitor cells. The current study evaluated the selectivity of ACE2 inhibitors, MLN-4760 and DX-600, and ACE and ACE2 activities in human (hu) and murine (mu) bone marrow cells. Assays were carried out in hu and mu mononuclear cells (MNCs) and huCD34+ cells or mu-lineage-depleted (muLin-) cells, human-recombinant (rh) enzymes, and mu-heart with enzyme-specific substrates. ACE or ACE2 inhibition by racemic MLN-4760, its isomers MLN-4760-A and MLN-4760-B, DX600 and captopril were characterized. MLN-4760-B is relatively less efficacious and less-selective than the racemate or MLN-4760-A at hu-rhACE2, and all three of them inhibited 43% rhACE. In huMNCs, MLN-4760-B detected 63% ACE2 with 28-fold selectivity over ACE. In huCD34+ cells, MLN-4760-B detected 38% of ACE2 activity with 63-fold selectivity. In mu-heart and muMNCs, isomer B was 100- and 228-fold selective for ACE2, respectively. In muLin- cells, MLN-4760-B detected 25% ACE2 activity with a pIC50 of 6.3. The racemic mixture and MLN-4760-A showed lower efficacy and poor selectivity for ACE2 in MNCs and mu-heart. ACE activity detected by captopril was 32 and 19%, respectively, in huCD34+ and muLin- cells. DX600 was less efficacious, and more selective for ACE2 compared to MLN-4760-B in all samples tested. These results suggest that MLN-4760-B is a better antagonist of ACE2 than DX600 at 10 µM concentration in human and murine bone marrow cells, and that these cells express more functional ACE2 than ACE.
    Full-text · Article · Feb 2016 · European Journal of Pharmacology
  • Source
    • "In support of our data, Dong and co-workers[22]showed that ACE2 overexpression enhances plaque stability in a rabbit model of atherosclerosis by reducing macrophage infiltration, decreasing lipid deposition, lowering MMP-3 and MMP-9 activities, and increasing collagen content. Similarly, ACE2 gene deletion increased atherosclerotic vulnerability by increasing the intraplaque inflammatory profile232425. Therefore, the pharmacological activation of ACE2 by diminazene appears to be consistent with the previous studies evaluating ACE2 overexpression or deletion. "

    Full-text · Article · Jul 2015 · Atherosclerosis
    • "The present study does not show a metabolic benefit as neither glucose metabolism nor insulin sensitivity was altered in adult db/db mice ( > 14-week) treated with ACE2 activator. The effect of ACE2 activation on improving glucose metabolism is likely to be related to19, 35, 38, 39, 54, 55), the EDRs in aortas and the capacity of ROS production in primary cultured mouse endothelial cells and the plasma Ang (1-7) level are not different between ACE2 wild-type and deficient mice on normal chow. Moreover, the pharmacological inhibition of ACE2-Ang (1-7) did not impair EDRs in aortas from normal mice. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin-converting enzyme 2 (ACE2) - angiotensin (1-7) [Ang (1-7)]-Mas constitutes the vaso-protective axis and is demonstrated to antagonize the vascular pathophysiological effects of the classical renin-angiotensin system. We sought to study hypothesis that upregulation of ACE2-Ang (1-7) signaling protects endothelial function through reducing oxidative stress that would result in beneficial outcome in diabetes. Ex vivo treatment with Ang (1-7) enhanced endothelium-dependent relaxation (EDR) in renal arteries from diabetic patients. Both Ang (1-7) infusion via osmotic pump (500 ng/kg/min) for 2 weeks and exogenous ACE2 overexpression mediated by adenoviral ACE2 via tail vein injection (109 pfu/mouse) rescued the impaired EDR and flow-mediated dilatation (FMD) in db/db mice. Diminazene aceturate treatment (15 mg/kg/day) activated ACE2, increased circulating Ang (1-7) level, and augmented EDR and FMD in db/db mouse arteries. In addition, activation of ACE2-Ang (1-7) axis reduced reactive oxygen species (ROS) over-production determined by dihydroethidium staining, CM-H2DCFDA fluorescence imaging, and chemiluminescence assay in db/db mouse aortas and also in high glucose-treated endothelial cells. Pharmacological benefits of ACE2-Ang (1-7) upregulation on endothelial function were confirmed in ACE2 knockout (ACE2 KO) mice both ex vivo and in vitro. Innovations: We elucidate that ACE2-Ang (1-7)-Mas axis serves as an important signal pathway in endothelial cell protection in diabetic mice, especially in diabetic human arteries. Endogenous ACE2-Ang (1-7) activation or ACE2 overexpression preserve endothelial function in diabetic mice through increasing nitric oxide bioavailability and inhibiting oxidative stress, suggesting the therapeutic potential of ACE2-Ang(1-7) axis activation against diabetic vasculopathy.
    No preview · Article · Apr 2015 · Antioxidants & Redox Signaling
Show more